Parnell Pharmaceuticals Holdings Ltd  

(Public, NASDAQ:PARN)   Watch this stock  
Find more results for Phyllis Edwards´┐Ż
-0.09 (-1.90%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.51 - 4.88
52 week 3.29 - 7.59
Open 4.88
Vol / Avg. 5,800.00/47,280.00
Mkt cap 61.65M
P/E     -
Div/yield     -
EPS     -
Shares 13.28M
Beta     -
Inst. own 66%
Jun 2, 2015
Parnell Pharmaceuticals Holdings Ltd at Jefferies Global Healthcare Conference
Apr 22, 2015
Q1 2015 Parnell Pharmaceuticals Holdings Ltd Earnings Call
Apr 22, 2015
Q1 2015 Parnell Pharmaceuticals Holdings Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -39.00% -
Operating margin -141.55% -
EBITD margin - -
Return on average assets - -
Return on average equity - -
Employees 51 -
CDP Score - -


Century Estate U 4 476 Gardeners Rd
+61-2-96674411 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Parnell Pharmaceuticals Holdings Ltd. is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product and research and development of pharmaceutical products for global animal health markets. It operates in four segments: Companion Animal, which covers its Osteoarthritis portfolios across both Canine and Equine species; Production Animal-U.S., which covers its Reproductive Hormone portfolio across Production Animal in the United States of America; Production Animal-Rest of World, which covers the its reproductive hormone portfolio in Production Animal across all regions outside of the United States of America and Manufacturing Operations is responsible for the operation its Food and Drug Administration approved sterile manufacturing facility and the manufacture and release of all its pharmaceutical products.

Officers and directors

Alan Bell Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Robert Joseph President, Chief Executive Officer, Director
Age: 37
Bio & Compensation  - Reuters
Brad McCarthy Chief Financial Officer, Director
Age: 38
Bio & Compensation  - Reuters
Edward J. Robb Chief Scientific Officer
Bio & Compensation  - Reuters
Matthew Musselman Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
Thomas E. Duley Director
Bio & Compensation  - Reuters
Phyllis I. Gardner M.D. Director
Age: 64
Bio & Compensation  - Reuters
David L. Greenwood Director
Age: 63
Bio & Compensation  - Reuters
Peter Molloy Independent Director
Age: 60
Bio & Compensation  - Reuters
Andrew J. Want Independent Director
Age: 52
Bio & Compensation  - Reuters